- Home
- NCZ vs AMRN Comparison
NCZ vs AMRN Comparison
Compare NCZ & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | AMRN |
|---|---|---|
| Founded | 2003 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.7M | 336.1M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | NCZ | AMRN |
|---|---|---|
| Price | $15.89 | $16.01 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 60.6K | ★ 78.9K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $12.62 | $12.96 |
| 52 Week High | $15.99 | $20.90 |
Technical Indicators
Market Signals| Indicator | NCZ | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 68.54 |
| Support Level | $14.88 | $13.58 |
| Resistance Level | $15.95 | $17.00 |
| Average True Range (ATR) | 0.31 | 0.66 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 91.40 | 89.83 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of current income, current gains and long-term capital appreciation. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.